drugset / Trial / NCT04283669
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Phase 2
Completed
12 enrolled
University of Alabama at Birmingham
Children's Hospital of Philadelphia · collabMemorial Sloan Kettering Cancer Center · collab
NaSingle-groupOpen-labelOther
Summary
Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.
Timeline
- Start
- 2020-02-18
- Primary completion
- 2025-02-25
- Completion
- 2025-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crizotinib | Small molecule | — | Oral |